Putting roadblocks on scientific & medical research on Cannabis #unacceptable
Make a Difference
Why Research Matters
The discovery of the Endocannabinoid system (ECS) is probably one of the most important scientific medical discovery in recent times. As our knowledge expands, we are coming to realize that the ECS is a master control system of virtually all physiology. However, In the United States of America, only 13% of the 157 medical schools surveyed taught any organized course on endocannabinoid science to our future doctors.
Current research merely scratches the surface of a vast and practically unexplored area of medical science, and as we learn more, we discover just how complex the activity of the Endocannabinoid system (ECS) truly is. For example, recent studies demonstrated that the endocannabinoid system is heavily involved in modulation of dopaminergic (releasing of dopamine as a neurotransmitter which are used by drugs in the treatment of Parkinson's and some psychiatric disorders) and Vanilloid signaling (these receptors when activated are involved in pain management), and that the activity of the cannabinoid receptors can vary wildly according to the area of the body, the genetic makeup of the individual and the individual’s current state of health.
Thousands of studies conducted in universities and research labs across the globe have also demonstrated that certain cannabinoids (THC, CBD, etc.) inhibit tumor growth by promoting cell death (apoptosis), reducing cell growth, stopping metastasis (blood and lymphatic spread of the cancer) and blocking the development of blood vessels (angiogenesis) that supply the tumor. Some of these research found that the cannabinoids, when used in combination, become even more potent killers of cancerous cells.
Understanding ECS and the effect of cannabis molecules on ECS can radicalize the current medical system of managing and treating complicated diseases.
However, key gaps remains between what has been researched in a petri dish and in animals in a laboratory settings versus what will be observed in clinical trials in humans for conclusive evidence on the therapeutic benefits of cannabis, understanding of the specific mechanisms involved, and how the outcomes may vary based on generic differences, type of disease, stage of the disease, dosage, toxicity, side effects and many other external factors. Only research and human clinical trial can help better understand the mechanisms by which cannabinoids could be utilized as adjunctive treatment of various diseases.
Since cannabis is currently classified as a Schedule 1 drug, Daner’s Hope Foundation is partnering with doctors, research institutes and universities that are currently working with various government bodies like FDA (Food and Drug Administration), DEA (Drug Enforcement Agency), NIDA (National Institute of Drug Abuse), NIH (National Institute of Health), HHS (Human and Health Services) and are able to overcome various federal and state regulatory hurdles to push scientific cannabis research and human clinical trials for cannabis in various medical treatments.